Literature DB >> 1645508

Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells.

A Bredberg1, M Brant, M Jaszyk.   

Abstract

The antibacterial activities of the fluorinated 4-quinolones (e.g., ciprofloxacin) have been ascribed to a marked inhibition of bacterial DNA gyrase. In contrast, the influence on purified mammalian DNA enzymes, including topoisomerases, has been reported to be several orders of magnitude weaker, occurring at concentrations higher than 100 micrograms of ciprofloxacin per ml. In this study, using a nondenaturing filter elution method, a marked induction of double-strand DNA breaks in human lymphoblastoid cells exposed to 80 micrograms of ciprofloxacin per ml was seen. The proportion of single-strand versus double-strand DNA breaks was similar to that seen with the topoisomerase II inhibitory antitumor agent VP-16. The cellular recovery was more rapid after treatment with ciprofloxacin than after treatment with VP-16, displaying a normal elution profile within 15 min at 37 degrees C (60 min for VP-16). These data indicate that ciprofloxacin has an effect on intracellularly located topoisomerase II in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645508      PMCID: PMC245030          DOI: 10.1128/AAC.35.3.448

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  X-ray induced DNA double strand break production and repair in mammalian cells as measured by neutral filter elution.

Authors:  M O Bradley; K W Kohn
Journal:  Nucleic Acids Res       Date:  1979-10-10       Impact factor: 16.971

2.  Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes.

Authors:  L L Shen; W E Kohlbrenner; D Weigl; J Baranowski
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

Review 3.  Recent studies of DNA topoisomerases.

Authors:  J C Wang
Journal:  Biochim Biophys Acta       Date:  1987-06-06

4.  Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro.

Authors:  Y S Bae; I Kawasaki; H Ikeda; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

5.  DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity.

Authors:  A J Wozniak; W E Ross
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

6.  Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts.

Authors:  P Hussy; G Maass; B Tümmler; F Grosse; U Schomburg
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

7.  DNA double-stranded breaks in mammalian cells after exposure to intercalating agents.

Authors:  W E Ross; M O Bradley
Journal:  Biochim Biophys Acta       Date:  1981-06-26

8.  4-Quinolone antibiotics: positive genotoxic screening tests despite an apparent lack of mutation induction.

Authors:  A Bredberg; M Brant; K Riesbeck; Y Azou; A Forsgren
Journal:  Mutat Res       Date:  1989-03       Impact factor: 2.433

  8 in total
  11 in total

1.  Inhibition of O6-alkylguanine-DNA alkyltransferase and DNase I activities in vitro by some alkylating substances and antineoplastic agents.

Authors:  A Link; K Tempel
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.

Authors:  Katherine A Hurley; Thiago M A Santos; Molly R Fensterwald; Madhusudan Rajendran; Jared T Moore; Edward I Balmond; Brice J Blahnik; Katherine C Faulkner; Marie H Foss; Victoria A Heinrich; Matthew G Lammers; Lucas C Moore; Gregory D Reynolds; Galen P Shearn-Nance; Brian A Stearns; Zi W Yao; Jared T Shaw; Douglas B Weibel
Journal:  Medchemcomm       Date:  2017-02-27       Impact factor: 3.597

3.  Limited effects of temafloxacin compared with ciprofloxacin on T-lymphocyte function.

Authors:  K Riesbeck; A Forsgren
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  Ciprofloxacin induces an immunomodulatory stress response in human T lymphocytes.

Authors:  K Riesbeck; A Forsgren; A Henriksson; A Bredberg
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

5.  Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice.

Authors:  Scott A LeMaire; Lin Zhang; Wei Luo; Pingping Ren; Alon R Azares; Yidan Wang; Chen Zhang; Joseph S Coselli; Ying H Shen
Journal:  JAMA Surg       Date:  2018-09-19       Impact factor: 14.766

6.  Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282.

Authors:  W E Kohlbrenner; N Wideburg; D Weigl; A Saldivar; D T Chu
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

7.  Treatment of mycoplasma contamination in a large panel of cell cultures.

Authors:  H G Drexler; S M Gignac; Z B Hu; A Hopert; E Fleckenstein; M Voges; C C Uphoff
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-05       Impact factor: 2.416

8.  Ciprofloxacin-induced G2 arrest and apoptosis in TK6 lymphoblastoid cells is not dependent on DNA double-strand break formation.

Authors:  Daniel J Smart; H Dorota Halicka; Frank Traganos; Zbigniew Darzynkiewicz; Gary M Williams
Journal:  Cancer Biol Ther       Date:  2007-10-08       Impact factor: 4.742

9.  Kinetics of γH2AX and phospho-histone H3 following pulse treatment of TK6 cells provides insights into clastogenic activity.

Authors:  Steven M Bryce; Stephen D Dertinger; Jeffrey C Bemis
Journal:  Mutagenesis       Date:  2021-07-07       Impact factor: 2.954

10.  The effect of ciprofloxacin on sperm DNA damage, fertility potential and early embryonic development in NMRI mice.

Authors:  Fatemeh Zobeiri; Rajab-Ali Sadrkhanlou; Siamak Salami; Karim Mardani; Abbas Ahmadi
Journal:  Vet Res Forum       Date:  2012       Impact factor: 1.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.